Which has better earnings & valuation, IMMX or VKTX?

Immix Biopharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is IMMX or VKTX more profitable?

Immix Biopharma's return on equity of -38.44% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Viking Therapeutics N/A -94.56% -82.75%

Does the media prefer IMMX or VKTX?

In the previous week, Viking Therapeutics had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for Viking Therapeutics and 5 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.24 beat Viking Therapeutics' score of 0.73 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RCUS or IMMX?

In the previous week, Immix Biopharma had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for Arcus Biosciences. Immix Biopharma's average media sentiment score of 1.24 beat Arcus Biosciences' score of 1.05 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMMX or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Tango Therapeutics N/A -25.75% -23.36%

Does the media prefer IMMX or TNGX?

In the previous week, Immix Biopharma had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for Tango Therapeutics. Immix Biopharma's average media sentiment score of 1.24 beat Tango Therapeutics' score of 0.90 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IMMX or AMLX?

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A Amylyx Pharmaceuticals N/A N/A -$144.74M -$1.43 N/A

Is IMMX or AMLX more profitable?

Immix Biopharma's return on equity of -38.44% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media prefer IMMX or AMLX?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 5 mentions for Immix Biopharma. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Immix Biopharma's score of 1.24 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMMX or IOVA?

In the previous week, Immix Biopharma had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.75 beat Immix Biopharma's score of 1.24 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immix Biopharma (IMMX) Competitors

$12.14 -0.56 (-4.41%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.50 +0.36 (+2.97%)

As of 09/11/2026 07:30 PM Eastern

Compare

IMMX vs. VKTX, RCUS, TNGX, AMLX, and IOVA

Should you buy Immix Biopharma stock or one of its competitors? Immix Biopharma's main competitors and comparable companies include Viking Therapeutics (VKTX), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), Amylyx Pharmaceuticals (AMLX), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immix Biopharma compare to Viking Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Immix Biopharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for Viking Therapeutics and 5 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.24 beat Viking Therapeutics' score of 0.73 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Immix Biopharma's return on equity of -38.44% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Viking Therapeutics	N/A	-94.56%	-82.75%

Immix Biopharma currently has a consensus target price of $21.29, suggesting a potential upside of 75.34%. Viking Therapeutics has a consensus target price of $96.63, suggesting a potential upside of 202.14%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Immix Biopharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

Immix Biopharma beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Immix Biopharma had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for Arcus Biosciences. Immix Biopharma's average media sentiment score of 1.24 beat Arcus Biosciences' score of 1.05 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Immix Biopharma's return on equity of -38.44% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Immix Biopharma	N/A	-38.44%	-34.72%

Immix Biopharma has lower revenue, but higher earnings than Arcus Biosciences. Immix Biopharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Arcus Biosciences presently has a consensus price target of $38.30, suggesting a potential upside of 55.54%. Immix Biopharma has a consensus price target of $21.29, suggesting a potential upside of 75.34%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arcus Biosciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Summary

Immix Biopharma beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Tango Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Immix Biopharma currently has a consensus target price of $21.29, indicating a potential upside of 75.34%. Tango Therapeutics has a consensus target price of $43.46, indicating a potential upside of 82.77%. Given Tango Therapeutics' higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Immix Biopharma had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for Tango Therapeutics. Immix Biopharma's average media sentiment score of 1.24 beat Tango Therapeutics' score of 0.90 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tango Therapeutics' return on equity of -25.75% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Tango Therapeutics	N/A	-25.75%	-23.36%

Immix Biopharma has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A

Summary

Tango Therapeutics beats Immix Biopharma on 8 of the 14 factors compared between the two stocks.

How does Immix Biopharma compare to Amylyx Pharmaceuticals?

Immix Biopharma (NASDAQ:IMMX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A

Immix Biopharma has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 5 mentions for Immix Biopharma. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Immix Biopharma's score of 1.24 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma's return on equity of -38.44% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Immix Biopharma presently has a consensus target price of $21.29, indicating a potential upside of 75.34%. Amylyx Pharmaceuticals has a consensus target price of $36.50, indicating a potential upside of 15.43%. Given Immix Biopharma's higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Immix Biopharma beats Amylyx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Iovance Biotherapeutics?

Immix Biopharma (NASDAQ:IMMX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immix Biopharma has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Immix Biopharma's return on equity of -38.44% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Immix Biopharma has higher earnings, but lower revenue than Iovance Biotherapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Iovance Biotherapeutics	$263.50M	14.78	-$390.98M	-$0.73	N/A

Immix Biopharma has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Immix Biopharma had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.75 beat Immix Biopharma's score of 1.24 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immix Biopharma currently has a consensus price target of $21.29, indicating a potential upside of 75.34%. Iovance Biotherapeutics has a consensus price target of $8.89, indicating a potential upside of 3.36%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Immix Biopharma beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$868.48M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-13.80	14.25	275.24	25.29
Price / Sales	N/A	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	6.86	15.12	10.33	6.20
Net Income	-$29.44M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-12.72%	-4.34%	-3.32%	-2.35%
1 Month Performance	6.77%	-0.02%	-0.41%	-2.77%
1 Year Performance	478.10%	40.64%	19.21%	7.63%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	3.5807 of 5 stars	$12.14 -4.4%	$21.29 +75.3%	+446.8%	$868.48M	N/A	N/A	9	Positive News
VKTX Viking Therapeutics	2.951 of 5 stars	$33.50 -0.5%	$96.63 +188.4%	+24.2%	$3.93B	N/A	N/A	20	News Coverage Options Volume
RCUS Arcus Biosciences	3.4234 of 5 stars	$29.98 +0.9%	$37.80 +26.1%	+114.0%	$3.78B	$247M	N/A	500	Positive News Analyst Forecast
TNGX Tango Therapeutics	2.7702 of 5 stars	$22.32 -0.1%	$43.46 +94.7%	+247.7%	$3.77B	$53.81M	N/A	90
AMLX Amylyx Pharmaceuticals	3.9521 of 5 stars	$34.49 +2.0%	$36.50 +5.8%	+167.1%	$3.77B	N/A	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. VKTX, RCUS, TNGX, AMLX, and IOVA

How does Immix Biopharma compare to Viking Therapeutics?

Summary

How does Immix Biopharma compare to Arcus Biosciences?

Summary

How does Immix Biopharma compare to Tango Therapeutics?

Summary

How does Immix Biopharma compare to Amylyx Pharmaceuticals?

Summary

How does Immix Biopharma compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. VKTX, RCUS, TNGX, AMLX, and IOVA

How does Immix Biopharma compare to Viking Therapeutics?

Which has better earnings & valuation, IMMX or VKTX?

Does the media prefer IMMX or VKTX?

Is IMMX or VKTX more profitable?

Do analysts prefer IMMX or VKTX?

Do insiders and institutionals have more ownership in IMMX or VKTX?

Which has more risk & volatility, IMMX or VKTX?

Summary

How does Immix Biopharma compare to Arcus Biosciences?

Does the media refer more to RCUS or IMMX?

Is RCUS or IMMX more profitable?

Which has stronger earnings and valuation, RCUS or IMMX?

Do analysts prefer RCUS or IMMX?

Do institutionals & insiders hold more shares of RCUS or IMMX?

Which has more volatility & risk, RCUS or IMMX?

Summary

How does Immix Biopharma compare to Tango Therapeutics?

Do analysts rate IMMX or TNGX?

Does the media prefer IMMX or TNGX?

Which has more volatility & risk, IMMX or TNGX?

Do institutionals and insiders have more ownership in IMMX or TNGX?

Is IMMX or TNGX more profitable?

Which has preferable earnings & valuation, IMMX or TNGX?

Summary

How does Immix Biopharma compare to Amylyx Pharmaceuticals?

Which has preferable valuation and earnings, IMMX or AMLX?

Which has more risk & volatility, IMMX or AMLX?

Do institutionals & insiders have more ownership in IMMX or AMLX?

Does the media prefer IMMX or AMLX?

Is IMMX or AMLX more profitable?

Do analysts prefer IMMX or AMLX?

Summary

How does Immix Biopharma compare to Iovance Biotherapeutics?

Do insiders & institutionals have more ownership in IMMX or IOVA?

Is IMMX or IOVA more profitable?

Which has stronger earnings & valuation, IMMX or IOVA?

Which has more risk and volatility, IMMX or IOVA?

Does the media prefer IMMX or IOVA?

Do analysts prefer IMMX or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools